Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Behcet Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2017, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape. Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behcet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Behcet Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 1, 2, 3, 1 and 1 respectively. Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Behcet Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Behcet Disease (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Behcet Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Behcet Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Behcet Disease - Overview Behcet Disease - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Behcet Disease - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Behcet Disease - Companies Involved in Therapeutics Development AbbVie Inc Celgene Corp Cell Medica Ltd Coherus BioSciences Inc Genor BioPharma Co Ltd Novartis AG Panacea Biotec Ltd R Pharm Behcet Disease - Drug Profiles adalimumab - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress apremilast - Drug Profile Product Description Mechanism Of Action R&D Progress canakinumab - Drug Profile Product Description Mechanism Of Action R&D Progress DLX-105 - Drug Profile Product Description Mechanism Of Action R&D Progress infliximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress RPH-104 - Drug Profile Product Description Mechanism Of Action R&D Progress Behcet Disease - Dormant Projects Behcet Disease - Discontinued Products Behcet Disease - Product Development Milestones Featured News & Press Releases Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet Apr 15, 2015: Phase II Data for Apremilast in Behcet's Disease Published in The New England Journal of Medicine Apr 14, 2015: Delenex Announces New Clinical Data Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcet's Disease At EULAR May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet's Disease For Humira Pre-filled Syringe In Japan Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Behcet Disease, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Behcet Disease - Pipeline by AbbVie Inc, H1 2017 Behcet Disease - Pipeline by Celgene Corp, H1 2017 Behcet Disease - Pipeline by Cell Medica Ltd, H1 2017 Behcet Disease - Pipeline by Coherus BioSciences Inc, H1 2017 Behcet Disease - Pipeline by Genor BioPharma Co Ltd, H1 2017 Behcet Disease - Pipeline by Novartis AG, H1 2017 Behcet Disease - Pipeline by Panacea Biotec Ltd, H1 2017 Behcet Disease - Pipeline by R Pharm, H1 2017 Behcet Disease - Dormant Projects, H1 2017 Behcet Disease - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.